PMID- 18415832
OWN - NLM
STAT- MEDLINE
DCOM- 20080520
LR  - 20151119
IS  - 1532-4303 (Electronic)
IS  - 0277-0903 (Linking)
VI  - 45
IP  - 3
DP  - 2008 Apr
TI  - Reduction of the total IgE level by omalizumab in children and adolescents.
PG  - 233-6
LID - 10.1080/02770900701883782 [doi]
AB  - BACKGROUND: Current data from clinical studies show that patients with severe 
      allergic asthma experience a significant improvement from omalizumab. The early 
      and late allergic reactions are inhibited by formation of complexes with free 
      circulating immunoglobulin E (IgE), independent of which antigen activates the 
      allergic cascade. The dosage of omalizumab depends on body weight and IgE level, 
      yet no parameter has been established to guide dosage changes during therapy. The 
      aim of this study was to investigate the value of the determination of total IgE 
      by ADVIA Centaur assay to monitor the therapy progress. PATIENTS AND METHODS: 
      Nine patients, 8 to 17 years of age, received therapy with omalizumab due to 
      severe allergic bronchial asthma. In addition, the patients had pronounced 
      rhinoconjunctivitis, food allergy, insect sting allergy, and/or neurodermitis. 
      The total IgE in the serum (Sandwich-Immunoassay ADVIA Centaur) was measured in 
      the patients once monthly before each omalizumab injection as a potential 
      progress parameter. RESULTS: Six months after the beginning of therapy with 
      omalizumab, a significant decrease of the total IgE concentration was found, in 
      comparison to the baseline values (p < 0.01). In all patients, the tolerability 
      of omalizumab was very good; there was a reduction in the frequency of the asthma 
      exacerbations and rescue medications. The dosage of inhaled glucocorticoids could 
      be lowered. All patients reported a clearly improved quality of life. 
      CONCLUSIONS: The increase of the total IgE concentrations after administration of 
      omalizumab described in the literature could not be confirmed. The value of total 
      serum IgE as a progress parameter should be investigated in controlled studies 
      with regard to sensitivity and specificity of the respective assays. The 
      establishment of a test procedure for therapeutic monitoring appears urgently 
      necessary, so that the appropriate dosage of omalizumab is applied in children 
      and adolescents. Patients receiving omalizumab therapy should be closely 
      monitored.
FAU - Steiss, J O
AU  - Steiss JO
AD  - Pulmonology and Allergy, Department of Pediatrics, University of Giessen, 
      Germany. Jens-Oliver.Steiss@paediat.med.uni-giessen.de
FAU - Strohner, P
AU  - Strohner P
FAU - Zimmer, K P
AU  - Zimmer KP
FAU - Lindemann, H
AU  - Lindemann H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
CIN - J Asthma. 2009 Feb;46(1):102-3. PMID: 19191148
MH  - Adolescent
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*blood/drug therapy
MH  - Child
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Male
MH  - Omalizumab
EDAT- 2008/04/17 09:00
MHDA- 2008/05/21 09:00
CRDT- 2008/04/17 09:00
PHST- 2008/04/17 09:00 [pubmed]
PHST- 2008/05/21 09:00 [medline]
PHST- 2008/04/17 09:00 [entrez]
AID - 792190129 [pii]
AID - 10.1080/02770900701883782 [doi]
PST - ppublish
SO  - J Asthma. 2008 Apr;45(3):233-6. doi: 10.1080/02770900701883782.